COMPLETED RESEARCH: PRACTICE MANAGEMENT
Abstract #PM03

Safety of Switching e-Prescribing Platform Body Surface Area Calculation from DuBois & DuBois to Mosteller on Active Chemotherapy Doses

JHOP - March 2021 Vol 11 Special Feature - HOPA Abstracts, Chemotherapy

Presenters: Nick Crozier, PharmD, BCPS, Pharmacy Director, UNM Cancer Center, UNM Comprehensive Cancer Center; Ronald Kittson, PharmD, Clinical Pharmacy Supervisor, UNM Comprehensive Cancer Center

Co-Authors: Lisa Anselmo, PharmD, BCOP, Clinical Pharmacy Director, Pharmacy, UNM Hospitals; Branda Chalenunphonh, Student Pharmacist, UNM College of Pharmacy

Background: Body surface area (BSA) is used to calculate individual doses for chemotherapeutic agents.1 Default BSA calculation equations vary between e-prescribing platforms. At the University of New Mexico Comprehensive Cancer Center (UNMCCC) our e-prescribing platform used DuBois & DuBois; however, because of the complexity of the DuBois & DuBois equation, our nurses and pharmacists use Mosteller. To improve safety, we changed our e-prescribing platform calculation to Mosteller.

Objective: To determine whether switching BSA calculation from DuBois & DuBois to Mosteller results in clinical differences in dose or in outcomes for patients receiving chemotherapy.

Methods: The UNMCCC switched from the DuBois & DuBois to Mosteller BSA calculation on July 6, 2020. We collected data that included changes in BSA, therapeutic dose changes, and adverse event reporting. We extracted data for all chemotherapeutic agents that required BSA dosing between May 1, 2020, and August 10, 2020, to compare chemotherapy doses given to patients before and after the calculation switch date. Patients who received the same chemotherapeutic agent as part of the same regimen at least once before and after July 6, 2020, were included. Only the latest chemotherapy dose before July 6, 2020, and the earliest dose after July 6, 2020, were evaluated. We used each patient’s most recent height and weight before July 6, 2020, to calculate predicted Mosteller BSA. Finally, we examined individually all dose increases by ≥5%, for safety.

Results: A total of 227 patients who received a total of 367 doses were evaluated. In all, 234 doses had no change, 10 doses increased by 5% to 10%, and 6 doses increased by >10%. We calculated the predicted patient BSA change corresponding to 330 of the doses. Of the predicted BSA changes, 23% were expected to increase by ≥2.5% and 6.67% were expected to increase by 5% to 10%. Predicted BSA changes correlated poorly with dose changes (r2 = 0.0058). Most doses remained unchanged because of physician manual calculations, use of previous BSA option, and pharmacist dose adjustment and rounding. Dose increases of >10% were caused by changes in the patient’s weight and provider’s chemotherapy regimen adjustment. There were no adverse events reported or safety concerns.

Conclusion: Switching the e-prescribing platform BSA calculation from DuBois & DuBois to Mosteller resulted in an overall increase in our patients’ calculated BSA, without significant clinical impact on the patients’ dose or outcome. The change from DuBois & DuBois to Mosteller can be safely made in clinical practice for patients receiving active chemotherapy.

  1. Fancher KM, Sacco AJ, Gwin RC, et al. Comparison of two different formulas for body surface area in adults at extremes of height and weight. J Oncol Pharm Pract. 2016;22:690-695.
Related Items
Welcome to the First Annual Issue of HOPA Abstracts, 2021
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts
Continuous Pre-Dose Assessment of Laboratory Parameters Is Not Required for Patients with Multiple Myeloma Receiving Lenalidomide, Bortezomib, and Dexamethasone
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Multiple Myeloma
Correlation of BRAF Mutation Status in Circulating Tumor DNA with Tumor Biopsy and Clinical Outcomes in the COLUMBUS Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Biomarkers, Clinical Trials, Targeted Therapies
Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1b PAVO Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Cost of Cancer Management by Stage of Diagnosis Among Medicare Beneficiaries
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Cost of Care
Encorafenib plus Cetuximab, with or without Binimetinib, for BRAF V600E–Positive Metastatic Colorectal Cancer: Relationship Between Carcinoembryonic Antigen and Clinical Outcomes from BEACON CRC
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Colorectal Cancer
Incidence of Adverse Effects in Patients with Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia in Lymphoid Blast Crisis Receiving Ponatinib with or without Concomitant Azole Antifungals
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Adverse Events, Leukemia
In-Class Transition from Parenteral Bortezomib to Oral Ixazomib in Newly Diagnosed Multiple Myeloma: Updated Real-World Results from the Community-Based US MM-6 Study
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Multiple Myeloma
Real-World Dosing Patterns of Ruxolitinib Among Patients with Myelofibrosis: A US Community Oncology Practice
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Oncology Pharmacy Programs, Myelofibrosis
Results from informCLL, a Prospective Observational Registry: Prognostic Biomarker Testing, Treatment Patterns, and Dosing in 1461 Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
JHOP - March 2021 Vol 11 Special Feature published on April 9, 2021 in HOPA Abstracts, Clinical Trials, Leukemia, Lymphoma
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.